Skip to content

Bioavailability of Aronia Melanocarpa

Evaluating Kinetics and Bioavailability of Aronia Melanocarpa Extract in Healthy Young and Older Adults

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06306911
Enrollment
16
Registered
2024-03-12
Start date
2024-03-25
Completion date
2024-08-31
Last updated
2024-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioavailability, Kinetics

Brief summary

The main objective of this study is to study the bioavailability and kinetics of acute Aronia Melanocarpa supplementation in healthy young (18-35 years) and older adults (55-75 years) adults. During the test day, participants will ingest a drink consisting of Aronia Melanocarpa extract (AME). The bioavailability and kinetics of AME will be assessed via frequent blood sampling, urine collection, and faecal sampling, in which AME and metabolite profiles will be quantified.

Interventions

DIETARY_SUPPLEMENTAronia Melanocarpa extract

Aronia Melanocarpa extract (AME) consisting of a mixture of anthocyanins and other polyphenols

Sponsors

BioActor
CollaboratorINDUSTRY
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI between 18-35 kg/m2 * Systolic blood pressure \< 160 mmHg and diastolic blood pressure \< 100 mmHg * Stable body weight (weight gain or loss \< 3 kg in the past three months) * Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study

Exclusion criteria

* Smoking or smoking cessation \< 12 months * Severe medical conditions, including asthma, kidney failure, auto-inflammatory diseases, rheumatoid arthritis, diabetes mellitus, cardiovascular disease, gastrointestinal disorders such as Crohn's disease, colitis * Use of dietary supplements or medication affecting the main outcomes of the study (e.g. affecting gut metabolism, blood pressure medication) * Use of an investigational product within another biomedical intervention trial within the previous month * Abuse of drugs * More than 3 alcoholic consumptions per day * Known pregnancy or lactation * Known allergy to study product * Difficult venepuncture

Design outcomes

Primary

MeasureTime frameDescription
Aronia metabolites in bloodtime = 0 hours until t = 48 hoursConcentrations and quality of Aronia metabolites in blood analysed with LC-MS
Aronia metabolites in urinetime = 0 hours until t = 48 hoursConcentrations and quality of Aronia metabolites in urine analysed with LC-MS

Secondary

MeasureTime frameDescription
Aronia metabolites in fecestime = 0 hoursConcentrations and quality of Aronia metabolites in feces analysed with LC-MS
length - baseline characteristicstime = 0 hourslength
weight - baseline characteristicstime = 0 hoursweight
blood pressure (systolic and diastolic) - baseline characteristicstime = 0 hoursblood pressure

Countries

Netherlands

Contacts

Primary ContactSanne Ahles, Msc
s.ahles@maastrichtuniversity.nl+31437114555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026